300584.SZ
海辰药业
SZSE · Healthcare · C 制造业 · CN
CNY 32.79
−0.33%Year over year
Reported trailing growth
- Revenue
- +27.0%
- EBITDA
- —
- EBIT
- +7.4%
- EPS
- +6.0%
- Free cash flow
- —
- Operating cash flow
- -53.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.4%
- EBITDA
- +12.2%
- EBIT
- +15.5%
- Net income
- +9.0%
- EPS
- +9.0%
- Free cash flow
- +185.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026